Taysha Gene Therapies Inc (TSHA) — Capital Reinvestment Ratio
Latest as of December 2022:
0.16x
Taysha Gene Therapies Inc (TSHA) has a Capital Reinvestment Ratio of 0.16x as of December 2022, meaning it reinvests 0% of its operating cash flow ($14.28 Million) in capital expenditures ($2.31 Million). See TSHA free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.16x
Capex / Operating Cash Flow
Operating Cash Flow
$14.28 Million
USD
Capital Expenditures
$2.31 Million
USD
Data as of
Dec 2022
Most recent filing
Taysha Gene Therapies Inc Capital Reinvestment Ratio (2019–2019)
This chart tracks Taysha Gene Therapies Inc's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for Taysha Gene Therapies Inc (2019–2019)
Year-by-year Capital Reinvestment Ratio for Taysha Gene Therapies Inc from 2019 to 2019. For live market cap and broader valuation context, see TSHA stock market capitalisation.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2019 | 0.61x | $135.00K | $82.00K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow